BioCentury
ARTICLE | Company News

Scripps Research Institute, Opko deal

October 12, 2015 7:00 AM UTC

Scripps granted Opko worldwide rights to develop and commercialize antibiotics that inhibit lipoprotein signal peptidase (LSPA). The antibiotics were discovered using a high throughput screening tech...